Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01427374 · ClinicalTrials.gov registry record
Risk Factors for Coronary Artery Calcification and Left Ventricular Hypertrophy in Hemodialysis Patients
A clinical trial, sponsored by University of Alberta.
- Terminated
- Registry status
- 30
- Enrollment target
NCT01427374 is a clinical trial that was terminated before completion, run by University of Alberta. The registered enrollment target is 30 participants.
The verdict
NCT01427374 was terminated before completion, sponsored by University of Alberta.
- TERMINATED
- Registry status
- 30 participants
- Enrollment target
Study Summary
Individuals with kidney disease are at a higher risk for heart and vascular diseases, including heart attacks and strokes, than those with normal kidney function. The purpose of this research study is to collect information on the causes, complications and treatment of kidney disease. Patient characteristics, comorbid diseases and laboratory markers used in routine practice, as well as novel biochemical markers and genetic data will be collected to examine relationships between biochemical and genetic markers and cardiovascular risk. Information on the health history of incident hemodialysis and peritoneal dialysis patients will be captured using structured patient interviews and review of medical records. Blood and urine specimens will be collected at the time of dialysis initiation and stored in order to perform novel biochemical and genetic assays in the future. The overall goal of the CKDCS/LUCID study is improve understanding of cardiac-associated risks and to improve treatment in patients with kidney disease. A cardiac imaging substudy will be performed in a subset of patients enrolled. The goals of the substudy are to examine whether the risks of developing common cardiac-related complications (coronary artery calcification \[CAC\] and left ventricular hypertrophy \[LVH\]) are associated with certain medications taken by individuals on dialysis and whether these risks are modified by a genotypic predisposition.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2011-05 |
| Est. Completion | 2017-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01427374
The ClinicalTrials.gov registry entry for NCT01427374 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alberta, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01427374 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01427374 about?
NCT01427374 is a clinical study titled "Risk Factors for Coronary Artery Calcification and Left Ventricular Hypertrophy in Hemodialysis Patients". Individuals with kidney disease are at a higher risk for heart and vascular diseases, including heart attacks and strokes, than those with normal kidney function. The purpose of this research study is to collect information on the causes, complications and treatment of kidney disease. Patient charac...
What is the current status of trial NCT01427374?
This trial is currently terminated. The enrollment target is 30 participants. The study started on 2011-05. Estimated completion is 2017-12.
Who is sponsoring clinical trial NCT01427374?
This trial is sponsored by University of Alberta, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.